Dianthus Therapeutics Files 8-K on Officer/Director Changes
Ticker: DNTH · Form: 8-K · Filed: May 22, 2025 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | 8-K |
| Filed Date | May 22, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-governance, officer-changes, director-changes
TL;DR
Dianthus Therapeutics 8-K: Director/officer changes and votes filed 5/22.
AI Summary
Dianthus Therapeutics, Inc. filed an 8-K on May 22, 2025, reporting on the departure of directors or certain officers, the election of directors, the appointment of certain officers, and compensatory arrangements. The filing also covers the submission of matters to a vote of security holders. Dianthus Therapeutics, Inc. was formerly known as Magenta Therapeutics, Inc. until November 21, 2016.
Why It Matters
This filing indicates potential shifts in leadership and governance at Dianthus Therapeutics, which could impact the company's strategic direction and operational stability.
Risk Assessment
Risk Level: medium — Changes in directors and officers, along with votes by security holders, can signal internal shifts or strategic decisions that may carry inherent risks.
Key Players & Entities
- Dianthus Therapeutics, Inc. (company) — Registrant
- Magenta Therapeutics, Inc. (company) — Former company name
- May 22, 2025 (date) — Date of report
- November 21, 2016 (date) — Date of name change
FAQ
What specific changes were made regarding directors or officers?
The filing indicates "Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers" as an item of report, but does not detail the specific individuals or changes within this 8-K document itself.
Were there any specific matters submitted to a vote of security holders?
Yes, the filing states "Submission of Matters to a Vote of Security Holders" as an item of report, but the details of these matters are not provided in this document.
What is the primary business of Dianthus Therapeutics, Inc.?
Dianthus Therapeutics, Inc. is in the "PHARMACEUTICAL PREPARATIONS" industry, with SIC code 2834.
When did Dianthus Therapeutics, Inc. change its name?
The company changed its name from Magenta Therapeutics, Inc. on November 21, 2016.
What is the principal executive office address for Dianthus Therapeutics, Inc.?
The principal executive offices are located at 7 Times Square, 43rd Floor, New York, New York, 10036.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on May 22, 2025 regarding Dianthus Therapeutics, Inc. /DE/ (DNTH).